4.8 Article

Progress toward treatments for synaptic defects in autism

Journal

NATURE MEDICINE
Volume 19, Issue 6, Pages 685-694

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3193

Keywords

-

Funding

  1. Institut Pasteur
  2. Bettencourt-Schueller foundation
  3. Centre National de la Recherche Scientifique
  4. University Paris Diderot
  5. Agence Nationale de la Recherche [ANR-08-MNPS-037-01-SynGen]
  6. Neuron-ERANET (EUHF-AUTISM)
  7. Fondation de France
  8. Conny-Maeva Charitable Foundation
  9. Cognacq Jay Foundation
  10. Orange Foundation
  11. Fondamental Foundation
  12. Innovative Medicines Initiative Joint Undertaking [115300]
  13. European Union
  14. European Federation of Pharmaceutical Industries and Associations

Ask authors/readers for more resources

Autism spectrum disorder (ASD) encompasses a range of disorders that are characterized by social and communication deficits and repetitive behaviors. For the majority of affected individuals, the cause of ASD remains unknown, but in at least 20% of the cases, a genetic cause can be identified. There is currently no cure for ASD; however, results from mouse models indicate that some forms of the disorder could be alleviated even at the adult stage. Genes involved in ASD seem to converge on common pathways altering synaptic homeostasis. We propose, given the clinical heterogeneity of ASD, that specific 'synaptic clinical trials' should be designed and launched with the aim of establishing whether phenotype 'reversals' could also occur in humans.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available